BiotechTube

KPI-121 Ophthalmic Suspension + Vehicle

Phase 3Completed
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Kerato Conjunctivitis Sicca

Conditions

Kerato Conjunctivitis Sicca

Trial Timeline

Jul 10, 2018 → Feb 5, 2020

NCT ID
NCT03616899

About KPI-121 Ophthalmic Suspension + Vehicle

KPI-121 Ophthalmic Suspension + Vehicle is a phase 3 stage product being developed by Kala Pharmaceuticals for Kerato Conjunctivitis Sicca. The current trial status is completed. This product is registered under clinical trial identifier NCT03616899. Target conditions include Kerato Conjunctivitis Sicca.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT03616899Phase 3Completed

Competing Products

20 competing products in Kerato Conjunctivitis Sicca

See all competitors
ProductCompanyStageHype Score
FK506Astellas PharmaPhase 3
77
FK506 + placeboAstellas PharmaPhase 3
77
OTX-101 0.09%Sun PharmaceuticalPhase 3
77
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%Sun PharmaceuticalPhase 3
77
OTX-101 0.05% + OTX-101 0.09% + VehicleSun PharmaceuticalPhase 2/3
65
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%Sun PharmaceuticalPhase 3
77
Diclofenac Sodium Gel 3% + Solaraze® (diclofenac sodium) Gel 3% + Vehicle Topical GelSun PharmaceuticalPhase 1
33
Imiquimod Topical Cream 3.75% + Zyclara® (imiquimod) Topical Cream 3.75% + Vehicle Topical CreamSun PharmaceuticalPhase 1
33
Imiquimod 5% manufactured by Taro + Aldara - Imiquimod 5% + Imiquimod Vehicle manufactured by TaroSun PharmaceuticalPhase 1
33
cyclosporine + vehicle of OTX-101Sun PharmaceuticalPhase 3
77
INS365 Ophthalmic SolutionMerckPhase 3
77
Pimecrolimus + VehicleNovartisPhase 2
52
Cyclosporine A + DexamethasoneNovartisApproved
85
RebamipideNovartisPhase 3
77
Investigational Treatment + Active comparatorNovartisPhase 2
52
RebamipideNovartisPhase 3
77
KX01 ointment 1% + PlaceboPharmaEssentiaPhase 3
76
Tasocitinib + Tasocitinib + vehicle for TasocitinibPfizerPhase 2
51
FluorouracilSanofiPhase 1/2
40
fluorouracil cream 0.5%SanofiApproved
84

Other Products from Kala Pharmaceuticals

loteprednol etabonate 0.25% ophthalmic suspensionApproved
77
KPI-121 1% Ophthalmic Suspension dosed BID + Vehicle of KPI-121 Ophthalmic Suspension dosed BIDPhase 3
69
KPI-121 1% + Prednisolone acetatePhase 3
69
KPI-121 0.25% Ophthalmic Suspension + Vehicle of KPI-121 0.25% Ophthalmic SuspensionPhase 3
69
KPI-121 0.25% + KPI-121 1.0% + Vehicle of KPI-121 0.25% + Vehicle of KPI-121 1.0%Phase 3
69